Amgen’s Soliris biosimilar clears phase 3, but won’t launch until 2025
pharmaphorum
AUGUST 24, 2022
Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion’s blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA. The post Amgen’s Soliris biosimilar clears phase 3, but won’t launch until 2025 appeared first on.
Let's personalize your content